Lupin reports completion of FDA inspection at Vizag plant with no observations

TAGS

Lupin said that the () has wrapped up a pre-approval and GMP inspection of its API manufacturing plant in , Andhra Pradesh.

The FDA inspection was undertaken from 6 March to 10 March 2023 and was completed without any observations.

— Lupin Managing Director said: “We are pleased with the successful completion of the inspection at our Vizag facility.

See also  ExeGi Pharma’s EXE-346 receives FDA orphan drug designation for pouchitis treatment

“This accomplishment is a testament to our commitment to upholding global quality standards across all our manufacturing sites, and to provide quality affordable healthcare for all.”

CATEGORIES
TAGS
Share This